Figure 4. Intraarterial hepatic perfusion and static planar imaging of the whole body (top panels) and tissue pieces (bottom panels).

(A-B) The combination of a reduction in the nontumoral epitope bioavailability and administration of PE-conjugated ME-9F1 into the hepatic artery led to preferential accumulation of labeled mAb in tumor vessels and resulted in the high tumor:liver ratio. *p<0.05. (C) Combination of bioavailability blockade of nontumoral epitopes and intra-arterial perfusion with I¹²⁵-conjugated ME-9F1 mAb in a tumor-bearing mouse. Multiple small HCCs and one large tumor were macroscopically identified in the liver. Tumor tissue produced a strong signal, whereas a very weak signal was detected in the liver. T, tumor; L, liver. (D) Combination of nontumoral epitope blockade and intra-arterial perfusion with I¹²⁵-conjugated ME-9F1 mAb in a tumor-free mouse. Weak signal in the liver was detected. (E) Intraportal perfusion with I¹²⁵-conjugated ME-9F1 mAb without blockade in a tumor-free mouse. Strong signal in the liver tissue was detected.